EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Insolvency
Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration

16-Jul-2026 / 23:10 CET/CEST

Korneuburg, Austria, 16th July 2026 – Marinomed Biotech AG (VSE:MARI) announces the plan to apply for the initiation of a court restructuring proceeding without self-administration. The application is being filed because the court-approved restructuring plan dated November 14, 2024, cannot be fulfilled due to the breakdown of negotiations by Unither and the failure of Unither Pharmaceuticals to make earn-out payments from the sale of the Carragelose business unit, thereby placing the company at risk of insolvency. The aim of the renewed restructuring proceedings without self-administration is to secure the company's financial stability by concluding a new restructuring plan. In addition to further restructuring measures, the legal options available against Unither arising from the sale of the Carragelose business and the assets of the Marinosolv platform are to be utilized.
+++ End of ad-hoc announcement +++

End of Inside Information

Language:	English
Company:	Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria
Phone:	+43 2262 90300
E-mail:	office@marinomed.com
Internet:	www.marinomed.com
ISIN:	ATMARINOMED6
WKN:	A2N9MM
Listed:	Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official Market)
LEI Code:	529900GN3B1EN80XF405
EQS News ID:	2367244